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 Abstract 
Introduction: The Coronavirus 2(SARS-CoV-2) outbreak spread rapidly in Italy and the lack of 
intensive care unit(ICU) beds soon became evident, forcing the application of noninvasive 
respiratory support(NRS) outside the ICU, raising concerns over staff contamination. We aimed to 
analyze the safety of the hospital staff, the feasibility, and outcomes of NRS applied to patients 
outside the ICU. 
Methods: In this observational study, data from 670 consecutive patients with confirmed COVID-19 
referred to the Pulmonology Units in nine hospitals between March 1st and May 10th,2020 were 
analyzed. Data were collected including medication, mode and usage of the NRS (i.e. high-flow nasal 
cannula (HFNC), continuous positive airway pressure (CPAP), noninvasive ventilation(NIV)), length of 
stay in hospital, endotracheal intubation(ETI) and deaths. 
Results: Forty-two health-care workers (11.4%) tested positive for infection, but only three of them 
required hospitalization. Data are reported for all patients (69.3% male), whose mean age was 68 
(SD 13) years. The PaO2/FiO2 ratio at baseline was 152+79, and the majority of patients (49.3%) were 
treated with CPAP. The overall unadjusted 30-day mortality rate was 26.9% with 16%, 30%, and 30%, 
while the total ETI rate was 27% with 29%, 25% and 28%, for HFNC, CPAP, and NIV, respectively, and 
the relative probability to die was not related to the NRS used after adjustment for confounders. ETI 
and length of stay were not different among the groups. Mortality rate increased with age and 
comorbidity class progression. 
Conclusions: The application of NRS outside the ICU is feasible and associated with favourable 
outcomes. Nonetheless, it was associated with a risk of staff contamination. 
Introduction 
On February 20th 2020, Coronavirus disease 19 (COVID-19) severely hit the Northern part of 
Italy. It was reported that, in Lombardy, the most populated region of the country, more 
 than 1500 patients required intensive care unit (ICU) admission over only 4 weeks, largely 
exceeding the actual capacity (1). In the same period, the number of hospital admissions 
was 7285 (2). Approximately 35% of these patients experienced Acute Respiratory Failure 
(ARF) requiring any form of respiratory support. A mathematical model of the occupation of 
intensive care resources in Italy predicted saturation of the theoretically available beds in 
the national territory by mid-April 2020 (3). 
Under these circumstances, despite extraordinary efforts aimed at increasing the availability 
of ICU resources, the Italian Societies of Respiratory Medicine proposed a protocol to 
provide ventilatory support outside the ICU in dedicated Respiratory COVID Units, 
reinforced by a higher number of nurses and noninvasive monitoring (4). This 
recommendation was somehow in contrast to most of the available guidelines that 
contraindicated using noninvasive respiratory support (NRS) in these patients due to the 
major concerns over using bio-aerosol producing techniques, because of possible 
contamination of the hospital staff (5). 
This “emergency” situation gave us the unique opportunity to challenge the hypothesis that 
NRS should not be used outside the ICU during pandemics. We have therefore analyzed the 
feasibility and safety, in terms of staff contamination, of NRS applied to severely ill patients 
outside the ICU. Patients’ characteristics and clinical outcomes were also analyzed. 
Methods 
The study was conducted in four out of five hospitals in the Area Vasta Emilia network and 
in five hospitals in the neighbouring regions, serving a population of approximately 8 million 
people. Institutional Review Boards reviewed the protocol and authorized prospective data 
collection. Informed consent was waived. A confirmed case of COVID-19 was defined as a 
patient with a positive result on high throughput sequencing or real-time reverse 
 transcriptase–polymerase chain reaction assay of nasal and pharyngeal swab specimens. 
Data were collected from registries of the Respiratory Disease Units coordinators at the nine 
hospitals identifying all of the patients receiving NRS outside the ICU. 
Excluding standard oxygen administration, patients were treated with three different types of NRS, 
namely high-flow nasal cannula (HFNC), continuous positive airway pressure (CPAP), or noninvasive 
ventilation (NIV), which also represented the three different groups in the analysis. 
The triage of patients was performed according to the Italian Respiratory Societies Joint Guidelines 
based on severity. In particular, the following categories were proposed: a) green (SaO2>94%, 
respiratory rate (RR)<20 breaths/min); b) yellow (SaO2<94%, RR>20 but responds to 10–15 L/min 
oxygen); c) orange (SaO2<94%, RR>20 but poor response to 10–15 L/min oxygen and requiring 
CPAP/NIV with very high FiO2); d) red (SaO2<94%, RR>20 but poor response to 10–15 L/min oxygen, 
CPAP/NIV with very high FiO2 or presenting respiratory distress with PaO2/FiO2<200 and requiring 
ETI and intensive care). Patients belonging to these latter two categories were therefore considered 
eligible for NRS in dedicated respiratory COVID areas (see below) set up for the isolation of 
confirmed cases and ARF treatment.   
These patients were not “usually” treated outside the ICU but, given the “emergency” situation, the 
lack of ICU beds and only once multiorgan disfunction was excluded, they still resulted eligible for an 
NRS trial. 
The transfer of severely ill patients to the ICU for intubation, with compromised haemodynamic 
parameters, low PaO2/FiO2 or ’not responding to NRS’, was discussed with the intensivists, based on 
prognosis, and obviously was only possible if beds were available. 
Although not specifically mentioned in the guidelines, HFNC was also used in these two categories, 
during breaks in ventilation or as a stand-alone support.  
 The use of helmet CPAP devices was suggested as first-line treatment, mainly for safety reasons. 
Clearly, this technique requires a sufficient supply of helmet interfaces (which ran out quite rapidly) 
and a high flow of O2 (which exceeded the O2 capacity in some hospitals), so that NIV and HFNC were 
used as alternatives, the first when it was necessary to “save” oxygen, and the second when CPAP 
availability finished. 
The respiratory COVID areas consisted mainly of two different units, both present in all of 
the hospitals. The first one, formerly a respiratory ward, was an ad-hoc dedicated 
Respiratory Monitoring Unit consisting of specialized monitored areas with an active full-day 
shift run by a fixed group of pulmonologists and with a “reinforced” nurse–patient ratio 
varying from 1:4 to 1:6 depending on the hospital. The second unit, called Respiratory 
Intermediate Care Units, consisted of a fixed medical team. These had a monitoring system 
similar to that of the Respiratory Monitoring Units, together with the availability of ICU 
ventilators and a nurse–patient ratio from 1:2 to 1:4, where more severely affected patients 
were usually treated. 
Patients were continuously monitored with electrocardiogram trace, noninvasive blood 
pressure, arterial oxygen saturation, and respiratory rate (RR). Intensive Care Medicine 
doctors were eventually available around the clock at the request of the ward teams. Great 
care was taken to keep a distance of >1.5 metres between each bed and to provide natural 
ventilation and airflow of at least 160 L·s–1 per patient. 
Concerning staff protection, first of all, courses were quickly organized for staff in the correct use of 
personal protective equipment (PPE), dressing and undressing. Filtering facepiece class 3 (FFP3) or 
FFP2 masks, double non-sterile gloves, long-sleeved water-resistant gowns, goggles or face shields 
were mandatory in the presence of aerosol producing procedures. 
 NIV was delivered mainly by dedicated single circuit NIV platforms provided with an oxygen blender 
and ad-hoc filters placed in the single tube circuit before the non-rebreathing devices to minimize 
bio-aerosol dispersion, or by ICU ventilators. HFNC was delivered using standard devices (Nasal High 
Flow Therapy, Fisher and Paykel Healthcare Ltd, New Zealand), while helmet CPAP dedicated 
devices, designed for pandemics, were simply activated by connecting them to the O2 source 
available in the hospital with blender systems applied to obtain adequate values of delivered FiO2 
(Intersurgical SpA, Mirandola, Italy and Dimar srl, Medolla, Italy). 
Data collection 
Data were collected prospectively from registries of the Respiratory Disease Units 
identifying all of the patients receiving NRS outside the ICU. 
Variables recorded for each patient were obtained for the period from March 1st until May 
10th 2020 and included the following: demographics (age, sex), comorbidities (type and 
number), respiratory condition at admission (respiratory rate (RR), PaO2/FiO2 ratio), 
medications (type of drugs prescribed), mode and usage of the NRS (ventilatory settings for 
NIV and CPAP, and flow rate for HFNC), and stay in hospital (days). The number of patients 
who died, either in the respiratory unit or in the hospital, and the patients who received 
endotracheal intubation (ETI) within the same time frame were recorded. Patients who 
were still hospitalized at the time of data analysis were excluded. 
The health status of the staff working in the respiratory unit was closely monitored. All staff 
with fever or respiratory symptoms underwent chest radiography, and nasal and pharyngeal 
swab specimens were taken. Serology for SARS-CoV-2 antibodies and pharyngeal swab was 
also periodically performed for all staff. 
Statistical analysis 
 No statistical sample size assessment was performed a priori, and sample size was the 
number of patients treated during the study period in the participant centres. Baseline 
characteristics of patients treated with HFNC, CPAP and NIV were compared. Across the 
treatment subgroups, continuous variables were expressed as means and standard 
deviation (SD) and were compared with the Kruskal–Wallis test and one-way ANOVA test, 
while categorical variables were expressed as numbers and percentages (%) and were 
compared using the χ2 test or Fisher’s exact test. Percentages of available data for the 
overall study population were based on the total number of patients included in the study, 
while the distribution of available data over the treatment subgroups was based on the 
available data for that variable, and the percentages were calculated using the number of 
available data for that subgroup. The fraction of infected professional health care workers 
was presented as numerical and percentage values. The association between ventilatory 
treatment and clinical outcomes was calculated using a logistic regression model. The 30-
day mortality rate was calculated adjusted for baseline confounders (age, P/F ratio, steroid 
usage and number of comorbidities). 
Patients were grouped by age and PaO2/FiO2 ratio. Age groups were defined as follows: 21 
through 40 years; 41 through 50 years; 51 through 60 years; 61 through 70 years; 71 
through 80 years; 81 through 90 years; and 91 through 100 years. PaO2/FiO2 ratio groups 
were defined as follows: below 50 mmHg; 51 through 100 mmHg; 101 through 150 mmHg; 
151 through 200 mmHg; 201 through 250 mmHg; 251 to 300 mmHg. For age subgroups, 
patients were further stratified according to the presence of comorbidities as follows: 
patients with ≤2 comorbidities and patients with >2 comorbidities. A dedicated composite 
index including 30-day mortality and intubation rate, was also considered. 
 The main clinical outcomes were presented across the age and comorbidity subgroups and 
across PaO2/FiO2 ratio strata. Continuous variables were expressed as means and SD and 
compared with the Kruskal–Wallis test and one-way ANOVA test while χ2 or Fisher’s exact 
test was used to compare categorical variables between median age and comorbidity 
subgroups as appropriate. A two-sided test of less than 0.05 was considered statistically 
significant. Statistical analyses were performed using SPSS version 25.0 (IBM Corp., Armonk, 
NY, USA) and GraphPad Prism version 8.4.1 (GraphPad Software, Inc., La Jolla, CA, USA) 
unless otherwise indicated. 
  
 Results 
A total of 704 patients were considered and of these, 670 patients were included and their data 
analyzed. Table 1 lists the patients’ characteristics. CPAP, as applied by helmet, was used on the 
majority of patients (Supplementary Table 1). Twenty-eight out of 670 (4.2%) had a Do Not Intubate 
(DNI) order. Figure 1 illustrates the patients’ allocation to NRS and clinical outcome. A total amount 
of 180 patients died at 30 days. Twenty of the 28 DNI patients died (9% of the total number of 
deaths). In total, 114 patients died on spontaneous breathing without an expressed written DNI 
order. 
Most of the study patients were male (69.3%). Hypertension, diabetes, dyslipidemia, obesity and 
chronic cardiovascular disorders were the comorbidities most represented, evenly distributed 
among the groups with the exception of obesity, which was more prevalent in the NIV group. 
Hydroxychloroquine, methylprednisolone, low molecular weight heparin and tocilizumab were the 
drugs most used for treatment. The frequency distribution of age and PaO2/FIO2 ratio in the whole 
study population are shown in Supplementary Figure 1. 
As shown in Table 2, 353 health care workers, including doctors, nurses, and health-care assistants, 
had been taking care of patients receiving NRS. Forty-two of them (12%) tested positive for SARS-
CoV-2 infection showing symptoms of mild (n=9) or moderate disease requiring hospitalization 
(n=3). All infected workers recovered well. The overall rate of workers infected, in personnel not 
specifically involved in the care of COVID-19 patients, in the nine hospitals was 3.8±1.9%. 
Table 3 illustrates the 30-day mortality rate in the overall population and in the three NRS subgroups 
with crude values and values adjusted for age, baseline PaO2/FiO2, number of comorbidities and 
steroid usage. The three modes of NRS had a similar impact on mortality outcome, as well as on 
intubation rate and length of stay. 
 In Table 4, outcome measures stratified by age-class and number of comorbidities are reported in 
the overall study population. Notably, the mortality rate increased with age-class progression and 
was significantly lower in younger (median ≤ 69 years) compared to older patients (> 69 years) 
(12.5% versus 41.2%, difference 28.7%, p<0.0001). Mortality rate was higher in highly comorbid 
patients compared with patients with <2 comorbidities (34.4% versus 19.6%, difference 14.8%, 
p=0.0006). The percentage of patients subjected to ETI was higher among younger patients and in 
patients with lower comorbidities compared to older and highly comorbid patients, although not 
reaching statistical significance in the latter comparison (34.3% versus 18.8%, difference 15.5%, 
p<0.001, and 29% versus 20.4%, difference 8.6%, p=0.06, respectively). No difference in length of 
hospital stay was present among the age and comorbidity classes (19.6 versus 20.6 days, p=0.3, and 
21.9 versus 22.1 days, p=0.9). 
Outcome measures stratified by PaO2/FiO2 ratio classes and according to NRS are reported in Table 
5. Patients with a PaO2/FiO2 ratio below 50 mmHg presented a higher 30-day mortality rate and a 
higher rate of ETI (p<0.001 and p<0.001, respectively). 
NRS settings are shown in Supplementary Table 1. NIV was used as much as the patients could 
tolerate and in a small percentage of cases (43/177=24%), HFNC was applied during the intervals. 
Patients with bilateral posterior infiltrates were also usually placed in the prone position for few 
hours a day, in all three NRS groups, with a schedule dependent on their tolerance. 
 Discussion 
This study showed that using NRS devices is feasible in patients with ARF due to SARS-CoV-2 
infection treated outside ICUs, in newly developed dedicated COVID Respiratory Monitoring 
Units, formerly respiratory wards, and in Respiratory Intermediate Care Units. 
Despite using the recommended PPE, a 11.4% contamination rate was observed among 
healthcare workers treating the infected patients. 
After adjusting for potential confounders, 30-day mortality rates using HFNC, CPAP and NIV 
were not significantly different. 
One of the major concerns of using bio-aerosol generating devices is that healthcare 
workers are at high risk of contracting the infection and therefore most international 
guidelines recommend being cautious or even contraindicate their use (6–8). Nevertheless, 
WHO advocate using CPAP or NIV for the management of respiratory failure in COVID-19 
patients, provided that appropriate PPE is worn by the personnel (9). 
Several studies have found that the maximum exhaled air dispersion via different oxygen 
administration and ventilatory support strategies is minimal for CPAP through an oronasal 
mask or NIV through a helmet equipped with an inflatable neck cushion, and is much less 
when compared with any kind of oxygen delivery system (10). 
Interestingly enough, so far, studies have been conducted in negative pressure hospital 
rooms with at least six air changes per hour (minimum number of air changes 
recommended by WHO is 12 per hour). When these rooms were not available, as was the 
case for most of our patients, alternative hospital areas including rooms with natural 
ventilation (expressed as the product of room volume and air change rate) of at least 160 
L·s–1 per patient were routinely employed, in keeping with the WHO statement (11). Indeed, 
according to the Italian recommendations (4), the large majority of our study population 
 received CPAP (by helmet or face mask), mask-NIV, and HFNC with a medical mask over the 
nasal prongs. 
Taking all these precautions into account and using all of the appropriate protection, the number of 
health workers who tested positive at serology or pharyngeal swab was still quite high (11.4%); 
however, those who became ill (12/369, i.e. 3.3% of the staff involved) were in line with the 3.5% of 
health care workers requiring hospital admission in China (12), the only study so far that has 
reported this outcome during the COVID-19 outbreak. One may claim that our staff could have been 
infected in the community rather than by exposure to NRSs; however, in the nine hospitals in this 
study, the overall rate of infection of health workers, in personnel not specifically involved in the 
care of COVID-19 patients. The dramatic and rapidly increasing wave of the pandemic obliged us to 
treat a high number of severely hypoxic patients with NRS outside the ICU. These patients are 
usually admitted to “protected” environments. The ATS/ERS Guidelines (13) for example suggested 
using NIV in de-novo respiratory failure only when managed by an experienced clinical team, and 
closely monitored in the ICU. Concerning the first point, all of the Units involved had extensive 
experience in NRS use over a long period, and the nurse–patient ratio was “unusually” high for a 
ward, since during the outbreak, the nursing staff was reinforced in the locations where the acutely 
ill patients were admitted. In addition, fully equipped noninvasive monitoring systems were 
available. 
This is by far the largest report on the use of NRS outside the ICU; however, our COVID 
dedicated Respiratory Units cannot be considered equivalent to the “usual” respiratory 
wards. Previous studies conducted in ICUs where NRS use was reported (1,15-21) account 
for 188 patients treated with NIV and 61 by HFNC, without showing their characteristics and 
severity or the outcomes (in all but one study). Interestingly, this latter study (19) showed a 
very high mortality rate both with NIV and HFNC (80% and 52%, respectively). Indeed, only a 
 few patients were treated in the respiratory ward or unit, namely 80 and 33 patients using 
NIV and HFNC respectively, with a poor survival rate (22,23). 
Despite the fact that comparison among studies is extremely difficult due to the potential 
heterogeneity of patients included and/or to differing local hospital organization, the failure 
rate (i.e. mortality and/or ETI) was much lower in our population, even when adjusted for 
potential confounders (see Table 3), and it was comparable to what was observed (26%) in a 
large Italian study performed in the ICU in patients mostly intubated and with a PaO2/FiO2 
ratio similar to ours (1). In addition, in a recent two-period retrospective case–control study, 
Oranger et al. (24) demonstrated that CPAP could avoid intubation at 7 days and at 14 days, 
particularly in COVID patients with a previous DNI decision. 
The mortality rate was similar with all of the NRS modes used after adjustment for confounders; 
however, it has to be noted that HFNC was usually applied in less sick patients compared with NIV 
and CPAP, and this may reflect the attitude of the clinicians to start these latter two modes in 
patients where they judged that applying a relatively high level of external positive end expiratory 
pressure (PEEP) was more appropriate. 
It has been suggested that using any form of NRS might unduly delay the start of ETI; however, it 
should be noted that 28 patients received a DNI order (20 of them died), and that an ICU bed was 
not promptly available at the time of deterioration, as reported in a specific small subset of the 
patient population. It may also be argued that “only” less than 5% of patients signed a DNI order. 
In Italy, the very large majority of the population are not sufficiently aware of the new 
Advanced Directive Law (25), or they do not want to complete in advance any document in 
this respect. Therefore, most of our patients arrived at hospital without any DNI or Do Not 
Resuscitate directives. The reasons for not proceeding to ETI in the absence of a written DNI 
order might be explained by: presumed lack of benefit from ETI or mechanical ventilation 
 (MV) based on clinical judgement, sudden death, or verbal refusal from the patient at the 
time of clinical deterioration. However, the majority of patients received “full treatment” 
when needed.  
Despite the fact that this retrospective analysis in a large population indicates that NRS may help to 
treat severely affected COVID-19 patients outside the ICU, in newly dedicated respiratory areas with 
experienced staff, it also presents three main limitations. First, the design was retrospective, like 
most of the studies published during this terrible period. Second, the decision to start one of the 
NRS modes was left to the attending physicians and mainly relied on the actual availability of 
equipment, so that the proportion of devices used was not evenly distributed. Third, as in most real-
life studies dealing with the COVID-19 pandemic (1), missing data may be quite relevant; however, 
the critical nature of the situation did not always allow detailed information to be collected. 
To conclude, this is the first observational, large multicentre study showing that the application of 
noninvasive respiratory devices outside the ICU is feasible but is associated with a risk of staff 
contamination; however, the retrospective study design precludes drawing firm conclusions about 
its effectiveness despite the fact that the mortality and intubation rates compare favourably with 
those of previous reports. 
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 Table 1. Demographic and clinical characteristics of the study population and according to cohort 1 
Variable 
Total 
n=670 (100%) 
Cohort 
p value 
  HFNC 
n= 163 (24.3%) 
 
CPAP 
n= 330 (49.3%) 
NIV 
= 177 (26.4%) 
 
Age, years (SD) 68.3 (13.3) 65.7 (14.7) 70.3 (12.1) 66.8 (13.5) <0.001 
Male, n (%) 464 (69.3) 114 (69.9) 223 (67.6) 127 (71.8) n.s. (0.6) 
SOFA, score (SD) 3.3 (1.7) 2.5 (0.9) 3.3 (1.7) 4 (1.9) <0.0001 
PaO2/FiO2, mmHg (SD) 152 (79) 166 (65) 151 (90) 138 (66) <0.01 
Respiratory rate, bpm (SD) 28 (7) 25 (5) 28 (7) 31 (7) <0.0001 
Comorbidities      
Hypertension, n (%) 311 (51.2) * 74 (47) § 153 (55) ç 84 (49) ^ n.s. (0.15) 
Dyslipidemia, n (%) 84 (15.8) ** 20 (12.6) § 53 (19.2) ç 11 (10.5) ^^ n.s. (0.06) 
Diabetes mellitus, n (%) 125 (20.6) * 32 (20.1) § 60 (21.7) ç 33 (19.1) ^ n.s. (0.82) 
Chronic cardiovascular disease, n (%)  105 (17.3) * 29 (18.2) § 54 (19.6) ç 22 (12.7) ^ n.s. (0.16) 
 Obesity, n (%) 108 (17.8) * 33 (20.8) § 31 (11.3) ç 44 (25.3) ^ <0.001 
Chronic kidney disease, n (%) 34 (6.4) ** 12 (7.6) § 17 (6.2) ç 5 (4.8) ^^ n.s. (0.59) 
COPD, n (%) 46 (7.6) * 9 (5.7) § 12 (4.4) ç 25 (14.5) ^ <0.001 
Chronic hepatic disease, n (%) 3 (0.6) ** 1 (0.6) § 2 (0.7) ç 0 (0) ^^ n.s. (0.71) 
Cancer, n (%) 53 (10) ** 17 (10.7) § 28 (10.1) ç 8 (7.6) ^^ n.s. (0.72) 
Treatment      
Hydroxychloroquine, n (%) 263 (82) ° 128 (91) @ 108 (72) % 27 (90) & <0.0001 
Lopinavir/ritonavir, n (%) 74 (23.1) ° 58 (41) @ 10 (7) % 6 (20) & <0.0001 
Darunavir/cobicistat, n (%) 47 (15) ° 37 (26) @ 9 (6) % 1 (3) & <0.0001 
Remdesivir, n (%) 2 (0.6) ° 1 (0.8) @ 1 (0.7) % 0 (0) & n.s. (0.89) 
Tocilizumab, n (%) 161 (34) °° 47 (34) @ 65 (28) %% 49 (50) && <0.001 
Methylprednisolone, n (%) 275 (69) °°° 105 (75) @ 113 (75) % 57 (58) && <0.01 
Prophylactic LMWH, n (%) 90 (35) °°°° 63 (45) @ 20 (21) %%% 7 (23) & <0.001 
Therapeutic LMWH, n (%) 130 (50) °°°° 69 (49) @ 48 (49) %%% 13 (43) & n.s. (0.78) 
 1 
 The data are presented as numerical and percentage values for dichotomic variables and as mean and standard deviation (SD) for 1 
continuous variables. Statistical significance was set for p<0.05. 2 
COPD = Chronic Obstructive Pulmonary Disease; LMWH = Low Molecular Weighted Heparin; SOFA = Subsequent Organ Failure Assessment; 3 
HFNC = High Flow Nasal Cannula; CPAP = Continuous Positive Airway Pressure; NIV = Noninvasive Mechanical Ventilation. 4 
*n=608, **n=532, §n=159, çn=276, ^n=173,^^n=105, °n=321, °°n=475, °°°n=400, °°°°n=259, °°°°n=259, @n=140, %n=151, 5 
%%n=229,n=%%%=97, &n=30, &&n=98. 6 
 Table 2. Fraction of active professional health care workers and percentage of infection 1 
Role At work Infected 
Physician, n (%) 108 8 (7.4) 
Nurse, n (%) 210 29 (13.8) 
Health care worker, n (%) 45 5 (11) 
Physiotherapist 16 0 (0) 
Total 369 42 (11.4) 
 2 
 3 
Data are presented as numerical and percentage values. 4 
 Table 3. Clinical outcomes and relative probability for the whole population and according to ventilatory support 
 
 
Outcome 
 Cohort 
Total 
n=670 
(100%) 
HFNC 
n= 163 
(24.3%) 
 
OR 
(95%CI) 
p 
value 
CPAP 
n= 330 
(49.3%) 
OR 
(95%CI) 
p 
value 
NIV 
= 177 
(26.4%) 
OR 
(95%CI) 
p 
value 
Crude 
30-day mortality, n 
(%) 
180 (26.9) 26 (15.9) 0.43 (0.3–0.7) <0.01 100 (30.3) 1.4 (0.9-2) 0.05 54 (30.5) 1.3 (0.5-1.9) 0.20 
Adjusted* 
   0.52 (0.2-1.2) 0.10  1.7 (0.8–4.3) 0.11  1.1 (0.3–3.7) 0.88 
           
Crude 
ETI, n (%) 178 (26.6) 47 (28.8) 1.1 (0.8-1.7) 0.45 82 (24.8) 0.8 (0.6-1.2) 0.32 49 (27.7) 1.1 (0.7-1.6) 0.80 
Adjusted* 
   1.5 (0.6–4.1) 0.39  0.9 (0.5-1.7) 0.76  1.2 (0.5–3.3) 0.65 
           
 Crude 
30-day mortality/ETI, 
n (%) 
312 (46.5) 62 (38) 0.6 (0.4–0.9) 0.01 156 (47.3) 1.06 (0.8-1.4) 0.7 94 (53) 1.4 (1.2) 0.04 
Adjusted* 
   0.89 (0.4-2.1) 0.79  0.9 (0.5-1.7) 0.76  1.1 (0.5-2.7) 0.78 
           
Length of hospital 
stay, days 
20.3 
(13.2) 
19.2 (13.3) 0.91 (0.4-1.13) 0.87 19.8 (12.1) 0.95 (0.5-1.14) 0.82 21.5 (15.1) 1.2 (0.6-1.5) 0.47 
 
 
Clinical outcomes and relative probability from fitting a logistic regression model for the whole study population and according to ventilatory 
support. The data are presented as numerical and percentage values for dichotomic variables and as mean and standard deviation (SD) for 
continuous variables. Statistical significance was set for p<0.05. 
HFNC = High Flow Nasal Cannula; CPAP = Continuous Positive Airway Pressure; NIV = Noninvasive Mechanical Ventilation; ETI= Endotracheal Intubation; OR = 
odds ratio. 
*Adjusted for age, baseline PaO2/FiO2, number of comorbidities and steroid usage. 
 Table 4. Clinical outcomes for the whole study population and stratified according to both age and comorbidity class 
 
 Patients by age, years, n (%) 
All 
N=670 
21–40 
n=19 (2.8) 
41–50 
n=46 (6.8) 
51–60 
n=106 (15.8) 
61–70 
n=176 (26.3) 
71–80 
n=195 (29.1) 
81–90 
n=112 (16.7) 
91-100 
n=16 (2.3) 
Overall 
Outcome, No, with data         
Died at 30 days, n (%) 180 (26.9) 0 (0) 7 (15.2) 6 (5.7) 31 (17.6) 71 (36.4) 55 (49.1) 10 (62.3) 
ETI, n (%) 178 (26.6) 7 (36.8) 12 (26.1) 36 (34) 65 (36.9) 48 (24.6) 10 (8.9) 0 (0) 
Length of hospital stay, days (SD) 20.3 (13.3) 16.8 (9.1) 19.1 (10) 20.6 (11.6) 22.7 (14.7) 21 (14.1) 16.6 (12.4) 13.7 (7.2) 
Patients with ≤2 comorbidities* 
N (%) 423 19 (4.5) 33 (7.8) 75 (17.7) 113 (26.7) 118 (27.) 58 (13.7) 7 (1.7) 
Outcome         
Died at 30 days, n (%) 83 (19.6) 0 (0) 5 (15.2) 6 (8) 18 (15.9) 40 (33.9) 12 (20.7) 2 (28.6) 
ETI n (%) 123 (29) 7 (36.8) 8 (24.2) 29 (38.7) 46 (40.7) 27 (22.9) 6 (10.3) 0 (0) 
Length of hospital stay, days (SD) 21.9 (15) 16.8 (9.1) 19.9 (11.1) 21.5 (12.4) 24.3 (15.6) 21.8 (14.7) 15.8 (11.3) 20.3 (5.9) 
Patients with >2 comorbidities* 
N (%) 122 0 (0) 4 (3.3) 13 (10.7) 33 (27) 47 (38.5) 23 (18.9) 2 (1.6) 
Outcome,         
 Died at 30 days n (%) 42 (34.4) --- 2 (50) 0 (0) 10 (30.3) 18 (38.3) 11 (47.8) 1 (50) 
ETI n (%) 25 (20.4) --- 1 (25) 3 (23.1) 14 (42.4) 6 (12.7) 1 (4.4) 0 (0 
Length of hospital stay, days (SD) 22.1 (15.6) --- 21.7 (8.8) 21.2 (10.9) 23.1 (16.1) 21.3 (14.7) 23.3 ( 21.5 (7.8) 
*Comorbidity status for those with outcome data was available for 545 patients. 
The data are presented as numerical and percentage values for dichotomic variables and as mean and standard deviation (SD) for continuous 
variables. 
HFNC = High Flow Nasal Cannula; CPAP = Continuous Positive Airway Pressure; NIV = Noninvasive Mechanical Ventilation; ETI= Endotracheal 
Intubation; SD=Standard Deviation. 
  
  
Table 5. Clinical outcomes 
and DNI state according to 
PaO2/FiO2 class 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Patients by PaO2/FiO2 strata, years, n (%) 
<50 
n=11 (1.6) 
 
51-100 
n=222 (33.1) 
101-150 
n=173 (25.8) 
151-200 
n=127 (18.9) 
201-250 
n=69 (10.3) 
251–300 
n=68 (10.1) 
 
Outcome         
Died at 30 days, n (%) 5 (45.5) 77 (34.7) 42 (24.2) 33 (26) 14 (20.3) 9 (13.2) 
ETI, n (%) 7 (63.6) 76 (34.2) 42 (24.3) 32 (25.2) 16 (23.2) 5 (7.4) 
Length of hospital stay, days (SD) 15.2 (10.1) 20.7 (14.6) 21.5 (14) 20.8 (12.5) 16.1 (9.8) 17.7 (9.8) 
DNI, n (%) 0 (0) 6 (2.7) 8 (4.6) 4 (3.1) 5 (7.2) 5 (7.4) 
 The data are presented as numerical and percentage values for dichotomic variables and as means and standard deviation (SD) for continuous 
variables. 
HFNC = High Flow Nasal Cannula; CPAP = Continuous Positive Airway Pressure; NIV = Noninvasive Mechanical Ventilation; ETI= Endotracheal Intubation; DNI, Do 
Not Intubate; SD=Standard Deviation. 
 Figure legends 
Figure 1. Patient allocation to NRS and related clinical outcomes. 
Legend. COVID19=Severe Acute Coronavirus (SARS-CoV2) induced Disease; ARF= Acute 
Hypoxic Respiratory Failure; DNI=Do not Intubate Order; NRS=Noninvasive respiratory 
support; HFNC = High Flow Nasal Cannula; CPAP = Continuous Positive Airway Pressure; NIV 
= Noninvasive Mechanical Ventilation; ETI= Endotracheal Intubation; SB=Spontaneous 
Breathing.  
Supplementary Figure 1. Frequency distribution of age classes and PaO2/FIO2 ratio in the 
whole population. 
 
 
 
 
 
 
 
 
 
 
 
 Table 1 
Support Value 
CPAP  
PEEP, cmH2O (SD)* 10.2 (1.6) 
Interface$  
Helmet, n (%) 149 (99) 
Facemask, n (%) 2 (1.3) 
NIV  
PEEP, cmH2O (SD) § 9.5 (2.2) 
Pressure support, cmH2O (SD) ^ 17.3 (3) 
Interface°  
Helmet, n (%) 15 (20.8) 
Facemask, n (%) 57 (79.2) 
HFNC  
Flow, L/min (SD) & 50.5 (8) 
 
 
Setting parameters according to support. The data are presented as a numerical and percentage 
value and as mean and standard deviation (SD) for continuous variables. 
HFNC = High Flow Nasal Cannula; CPAP = Continuous Positive Airways Pressure; NIV = Non-Invasive 
mechanical Ventilation 
*n=66, $n=151, §n=82, ^n=87, °n=72, &n=48 
 
  
  
